| Followers | 13 |
| Posts | 320 |
| Boards Moderated | 0 |
| Alias Born | 01/17/2021 |
Tuesday, November 16, 2021 12:22:18 PM
Maybe, just maybe ...
... Amarin was unwilling to support Rule 60 because they didn't want to be associated with conspiracy theorists and unsubstantiated claims of fraud. Maybe they didn't want to associate the Amarin name with a lawyer that filed a ridiculous judicial misconduct complaint against a judge for the offense of uttering the words "fish oil" in a newspaper interview. Maybe, if EPADI had had the good sense to focus on 'mistake' (ala Curfman) and leave all the hyperbolic claims aside, maybe Amarin would have supported the Rule 60 motion.
As a shareholder, I might have considered my own suit for incompetence if the company had stupidly stood next to a table only missing "P of intergroup differences was calculated using student unpaired t test" and said "Your honor, we agree this cropped table represents a fraud on the court of the highest order." If EPADI wants to go down this rabbit hole, no one should expect Amarin to follow them. There are legitimate reasons for criticizing Amarin. Not associating itself with a judicially-embarrassed shareholder's unsubstantiated claims of fraud is a plus and not a negative.
Amarin's non-participation is the result of corporate covering up of negligence
... Amarin was unwilling to support Rule 60 because they didn't want to be associated with conspiracy theorists and unsubstantiated claims of fraud. Maybe they didn't want to associate the Amarin name with a lawyer that filed a ridiculous judicial misconduct complaint against a judge for the offense of uttering the words "fish oil" in a newspaper interview. Maybe, if EPADI had had the good sense to focus on 'mistake' (ala Curfman) and leave all the hyperbolic claims aside, maybe Amarin would have supported the Rule 60 motion.
As a shareholder, I might have considered my own suit for incompetence if the company had stupidly stood next to a table only missing "P of intergroup differences was calculated using student unpaired t test" and said "Your honor, we agree this cropped table represents a fraud on the court of the highest order." If EPADI wants to go down this rabbit hole, no one should expect Amarin to follow them. There are legitimate reasons for criticizing Amarin. Not associating itself with a judicially-embarrassed shareholder's unsubstantiated claims of fraud is a plus and not a negative.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
